10-Q: Lisata Therapeutics Q1 2026 Update: Kuva Acquisition Progress & Financials

Lisata Therapeutics reports Q1 2026 results, detailing progress on its proposed acquisition by Kuva Labs, Inc., and a net loss of $4.49 million.

Summary

• Lisata Therapeutics reported a net loss of $4.49 million for the first quarter ended March 31, 2026, compared to a net loss of $4.72 million for the same period in 2025.
• Total operating expenses decreased by 15.5% to $4.9 million in Q1 2026 from $5.8 million in Q1 2025, primarily due to reduced research and development expenses.
• The company has a pending acquisition by Kuva Labs, Inc., with the tender offer date extended multiple times, most recently to May 29, 2026.
• Kuva Labs has agreed to cover certain of Lisata's expenses up to $1.1 million until the tender offer commences.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for the next twelve months, necessitating additional funding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net loss, substantial doubt about going concern, and significant delays in the proposed acquisition, despite some positive clinical trial data.

Positives

• Reduction in operating expenses by 15.5% to $4.9 million in Q1 2026 compared to Q1 2025.
• Research and development expenses decreased by 53.7% to $1.2 million, mainly due to the completion of the Bolster trial and reduced clinical department expenses.
• Kuva Labs will cover up to $1.1 million in expenses for Lisata until the tender offer begins, providing some short-term financial relief.
• The ASCEND trial's Cohort B showed promising results for certepetide in combination with chemotherapy for mPDAC, with a 45.2% ORR and 7.5 months mPFS.
• The company received a $0.7 million tax refund from the Australian Taxation Office for the 2024 tax year.

Negatives

• Reported a net loss of $4.49 million for Q1 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months.
• The proposed acquisition by Kuva Labs has experienced multiple delays in the commencement of the tender offer.
• General and administrative expenses increased by 15.2% to $3.7 million, primarily due to increased legal fees and consulting expenses related to the Kuva acquisition.
• The Phase 2a BOLSTER trial in cholangiocarcinoma showed no evidence of benefit when certepetide was added to standard of care.

Risks

• Failure to complete the proposed acquisition by Kuva Labs could have a material adverse effect on the business, operating results, financial condition, and stock price.
• The company's continued operations are dependent on its ability to raise additional funding, and there is substantial doubt about its ability to continue as a going concern.
• Delays in the commencement of the Kuva Labs tender offer and potential failure to meet closing conditions pose significant risks.
• If the Kuva acquisition does not close, the company may face decreased investor confidence, shareholder litigation, and difficulty retaining key personnel.
• The company may be required to delay or discontinue research and development programs if it cannot access necessary capital.

Future Outlook

The company anticipates incurring additional losses until it can generate significant revenues from its products. Its continued operations are dependent on raising additional funding through equity or debt offerings, or pursuing collaboration or licensing arrangements. Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the next twelve months. If additional funding is not obtained, the company may be required to curtail, delay, or discontinue its research and development programs.

Management Comments

• Management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of twelve months after the date these consolidated financial statements are issued.
• To meet our short and long-term liquidity needs, we expect to use existing cash balances and a variety of other means.
• Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake.

Industry Context

StockSavvy.ai notes that Lisata Therapeutics operates in the highly competitive and capital-intensive clinical-stage pharmaceutical sector, where success is contingent on advancing drug candidates through rigorous clinical trials and regulatory approvals. The proposed acquisition by Kuva Labs, if completed, would represent a significant event for Lisata, potentially providing an exit for investors and a path for its lead candidate, certepetide, to be further developed or commercialized under new ownership. The delays in the acquisition process highlight the complexities and uncertainties inherent in such transactions, especially for companies with ongoing liquidity concerns.

Comparison to Industry Standards

• The ASCEND trial's Cohort B results for certepetide in mPDAC (45.2% ORR, 7.5 months mPFS) show potential when compared to standard of care chemotherapy alone, which typically yields ORRs in the range of 20-30% and mPFS of 4-6 months in first-line mPDAC.
• The Qilu Phase 2 study in China showed a 41.5% ORR and 5.82 months median PFS, which is broadly in line with industry benchmarks for similar combination therapies in advanced pancreatic cancer.
• The company's net loss of $4.49 million for the quarter is within the expected range for a clinical-stage biotech company of its size, which often burn significant capital on R&D without generating revenue.
• The substantial doubt about going concern is a common concern for clinical-stage biotechs that have not yet achieved commercialization or secured substantial long-term funding.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (SBP), where Cend's founding shareholder was an executive at SBP. SBP was issued shares of common stock as consideration. The company is required to pay SBP an annual license maintenance fee and potential milestone payments, and royalties on net sales. The company is also obligated to pay SBP 25% of any sublicensing income received, which resulted in SBP receiving shares of Impilo's preferred stock.

Stakeholder Impact

• Shareholders face uncertainty due to the pending acquisition and potential delays or failure to complete the transaction, which could impact stock price.
• Employees may experience distraction and potential productivity decline due to the pending acquisition; retention of key personnel is a concern.
• Creditors and suppliers may be impacted by the company's going concern issues and need for additional funding.

Next Steps

• Kuva Labs is expected to commence its tender offer by May 29, 2026.
• The company will continue to seek additional funding through various means, including equity or debt offerings, and collaborations.
• Final study reports for the ASCEND trial are anticipated later in the year.
• Investigator-initiated trials are ongoing, with data announcements and final study reports dependent on the academic sponsors.

Key Dates

Recommendation

The pending acquisition by Kuva Labs at a stated price of $5.00 per share plus a CVR provides a floor for the stock price, suggesting a 'hold' recommendation. However, the significant delays in the acquisition, the company's ongoing financial struggles (going concern doubt), and the inherent risks of M&A transactions warrant caution. Investors should monitor the progress of the Kuva acquisition closely. If the deal falters, the outlook could significantly worsen, potentially justifying a 'sell' recommendation.

Keywords

Lisata Therapeutics, SEC Filing, 10-Q, Quarterly Report, Kuva Labs, Merger Agreement, Tender Offer, Certepetide, Clinical Stage, Pharmaceutical, Net Loss, Going Concern